# Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products

> **NCT04183491** · PHASE1 · COMPLETED · sponsor: **Food and Drug Administration (FDA)** · enrollment: 84 (actual)

## Conditions studied

- Healthy Subjects
- Pharmacokinetics
- Pharmacodynamics

## Interventions

- **BIOLOGICAL:** Interferon beta-1a
- **BIOLOGICAL:** Interferon beta-1a
- **BIOLOGICAL:** Interferon beta-1a
- **BIOLOGICAL:** Peginterferon beta-1a
- **BIOLOGICAL:** Peginterferon beta-1a
- **BIOLOGICAL:** Peginterferon beta-1a
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04183491
- **Lead sponsor:** Food and Drug Administration (FDA)
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-28
- **Primary completion:** 2021-01-26
- **Final completion:** 2021-01-26
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2024-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04183491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04183491, "Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04183491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*